Another example is vemurafenib (PLX4032 and RG7204), a selective BRAF serine–threonine kinase inhibitor inducing autophagy, which is employed in the treatment of advanced melanoma with a BRAF gene mutation (IC50 = 31 nM) [24]. This evidence concerns the gene BRAF and melanoma.